Cell Origin Biotech (hangzhou) Co., Ltd.

This early trial tests a new treatment called SY001, which uses a patient's own immune cells (macrophages) engineered to attack cancer cells that have a protein called mesothelin. The study includes just 2 people with advanced ovarian or pancreatic cancer who have not responded t…